Marshall Wace, LLP Immuneering Corp Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.28 - $2.75 $491,616 - $1.06 Million	384,075 New	384,075 $491,000
Q3 2022 Nov 14, 2022	BUY	$5.0 - $14.32 $335,800 - $961,731	67,160 New	67,160 $962,000
Q4 2021 Feb 14, 2022	SELL	$16.12 - $31.02 $211,961 - $407,881	-13,149 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $223,533 - $431,813	13,149 New	13,149 $349,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $49.9M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.